Form 4: Dynavax SVP Slebir's Equity Vesting Accelerates Amid Sanofi Merger

Dynavax Technologies SVP John L. Slebir's performance and restricted stock units accelerated vesting on December 23, 2025, in connection with a merger agreement with Sanofi.

Summary

• John L. Slebir, SVP General Counsel of Dynavax Technologies Corp (DVAX), reported changes in beneficial ownership of common stock.
• On December 23, 2025, the Board of Directors approved the acceleration of vesting for certain performance-based restricted stock units (PSUs) and restricted stock units (RSUs) due to an Agreement and Plan of Merger with Sanofi.
• 33,750 PSUs were earned at 125% of the target number, based on the Issuer's total stockholder return (rTSR) performance over a shortened period, with the merger agreement valuing shares at $15.50.
• 16,667 RSUs and 14,141 RSUs also vested due to acceleration.
• On December 24, 2025, 32,502 shares were withheld by the Issuer to satisfy tax withholding requirements on the vesting of PSUs and RSUs, at a price of $15.38 per share.
• Following these transactions, John L. Slebir beneficially owns 69,634 shares of common stock.
• The reported beneficial ownership includes 1,205 shares purchased through the Issuer's Employee Stock Purchase Plan on August 15, 2025.

Sentiment

Score: 8

Explanation: The filing reflects a highly positive event for the reporting person due to accelerated equity vesting and the company's shareholders due to the announced merger with Sanofi at a favorable price, indicating a successful outcome for the company's strategic direction.

Positives

• Acceleration of vesting for a significant number of performance-based restricted stock units (PSUs) and restricted stock units (RSUs) for the SVP General Counsel.
• PSUs were earned at 125% of the target number, indicating strong performance achievement based on the rTSR condition.
• The acceleration of vesting is directly linked to a merger agreement with Sanofi, implying a positive liquidity event for shareholders at $15.50 per share.

Negatives

• A substantial number of shares (32,502) were withheld by the Issuer to cover tax withholding requirements, reducing the net shares received by the reporting person.

Future Outlook

The filing indicates that Dynavax Technologies Corp is subject to an Agreement and Plan of Merger with Sanofi, which will result in the acquisition of Dynavax by Sanofi at a price of $15.50 per share. This suggests the company's future as an independent entity is limited, with a focus on completing the merger.

Industry Context

This transaction highlights ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger companies like Sanofi acquire smaller, specialized firms such as Dynavax to expand their portfolios or gain access to specific technologies. The acquisition price of $15.50 per share provides a benchmark for valuations in similar M&A activities within the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: The merger agreement with Sanofi at $15.50 per share provides a clear exit strategy and value realization for Dynavax shareholders.
• Employees (specifically the reporting person): Accelerated vesting of equity awards provides immediate liquidity and certainty regarding compensation tied to company performance and the merger event.

Next Steps

• Completion of the Agreement and Plan of Merger between Dynavax Technologies Corp and Sanofi.

Key Dates

Recommendation

The filing details transactions stemming from an announced merger agreement with Sanofi at $15.50 per share. For existing shareholders, holding the stock until the merger's completion is the standard recommendation to realize the agreed-upon acquisition price. New investment decisions would primarily hinge on the spread between the current market price and the offer price, factoring in the probability and timeline of merger completion.

Keywords

Dynavax Technologies, DVAX, Sanofi, Merger, Acquisition, Form 4, Insider Transaction, Restricted Stock Units, Performance Stock Units, Equity Vesting, Executive Compensation